~~<i id='AF4B5023AD'><strike id='AF4B5023AD'><tt id='AF4B5023AD'><pre id='AF4B5023AD'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：explore 2025-10-01 20:14:45 - browse：4672

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Lawmakers consider Medicare pay reforms for doctors

entertainment

Wikipedia

focus

hotspot

focus

AdobePharmacistsincreasinglyarebeingaskedtomakedrugsinbulkforhospitalsthatareinshortsupply,andthey’r

WSS

Lawmakers consider Medicare pay reforms for doctors

HHS leader on health, climate change and biopharma emissions

Why health workers in Gaza are injured or die at high rates

Study finds gene variants tied to breast cancer risk in Black women

NIH confirmation hearing shows politicization of research

Bird flu surveillance in wastewater gets boost from consortium

hotspot

leisure time

entertainment

Jerome Adams on the need for new antivirals for Covid

Studies point to risks of excluding people with obesity from drug trials

At least 13 dead in Texas as scorching temps continue

Making the case for fair compensation in clinical trials

Guidelines to prevent youth baseball injuries need more muscle

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Psychedelics group wrestles with new pharma identity

Researchers explore possible ties between long Covid, menopause

After affirmative action ruling, medical educators look to 'holistic review'

STAT Summit: Biotech founders on deal

Wikipedia

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Beam Therapeutics to lay off 20% of its staff, re

H5N1 bird flu outbreak: Second human case reported, in Michigan

STAT Summit: Michael J. Fox on progress in Parkinson's research

Hospital price transparency does save money, advocate argues

focus

hotspot

focus

focus